FDA panel backs lower dose of Lilly-Incyte arthritis drug over higher
(Reuters) - A rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp should not be approved at a higher dose, a U.S. Food and Drug Administration advisory committee voted on Monday, while backing the approval of a lower dose.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Arthritis | Food and Drug Administration (FDA) | Health | Rheumatoid Arthritis | Rheumatology